Fourth quarter 2020: Promising new product launches and adjusted EBITDA growth of 2.5x YoY

By Aker BioMarine, February 16, 2021


Aker BioMarine today announces its results for the fourth quarter 2020.

Fourth quarter highlights:

- Revenues of USD 75.5 million (USD 71.9 million in the corresponding period last year)

- Adjusted EBITDA of USD 21.1 million (USD 8.2 million), with 28% (11%) adjusted EBITDA margin in the quarter

- Net profit of USD 4.2 million (USD -17.8 million)

- Revenue growth of 17% for the full year, USD 289 million (USD 246 million)

- Adjusted EBITDA growth of47% for the full year, USD 78.1 million (USD 53.0 million)

- Continued strong onshore production through the quarter as well as for the full year, delivering record low unit cost

- Harvesting in the quarter was 2,500 MT vs. the expected range of 6,500 - 7,500 MT, lower due to krill appearing later than anticipated in area 48. Harvesting picked up to record levels in the beginning of 2021

- Kori continued to grow the consumer and customer base with new retailers coming in, including Sam’s Club, Rite Aid and Walgreens

- Launch of Lysoveta; a transporter molecule targeting the brain and eye segment. Established partnerships with University of Illinois Chicago for IP and research

- Signed pharma partnership with MD3, for development of five pharma-indications within the eye and brain segment

- Launch of Aion, a circular solution company, delivering fully traceable circular plastic products, also supporting Aker BioMarine’s ambition of full circularity of main waste streams. Plan to spin off in 2021/2022.


“It was an eventful year to say the least. Even in the face of Covid-19-related challenges in 2020, our business continued as usual thanks to the relentless efforts and dedication of our global team. We grew our top line by 17%, and we managed to onboard new customers and enter new markets amidst pervasive travel restrictions. I am pleased to see the scalability of Aker BioMarine’s business model coming to life, with a 2020 adjusted EBITDA growth of 47%. Despite the challenges and curveballs thrown at us in 2020, Aker BioMarine delivers strong financial numbers for the year, giving me great optimism for a promising and innovation-filled future,” said Matts Johansen, CEO of Aker BioMarine.



Fourth quarter 2020 Report
Fourth quarter 2020 Presentation (PPT)


For further information, please contact:

Martin Stenshall, Investor Relations

Mobile: +47 47 33 83 31


Latest from Aker BioMarine